Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
As featured in Microdose semaglutide delivers the same GLP-1 mechanism at a lower starting dose ideal for first-time patients who want to minimize side effects during ramp-up
Researchers tested the triple-dose of semaglutide in two clinical trials, one involving people with obesity and the other in people with obesity and type 2 diabetes
Your provider may recommend: Shorter time at the 2.5 mg initiation dose (3 weeks instead of 4) More aggressive titration to reach therapeutic levels sooner Targeting higher maintenance doses (12.5 to 15 mg) from the outset Closer monitoring of side effects to balance speed with tolerance The microdosing alternative for sensitive switchers Not everyone needs or wants to follow the standard titration
The standard titration schedule helps you adjust to this dual action
Final Thoughts GLP-1 medications have transformed how we treat obesity: Semaglutide broke ground with ~15% average weight loss
